XML 72 R65.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Loss per Share - Schedule of Potentially Dilutive Shares Were Not Included In The Calculation of Diluted Shares Outstanding (Details) - shares
6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Performance stock units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 2,676,300 6,690,750
DRSUs    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 4,276,875 3,637,905
Options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 73,698,315 64,289,090
Restricted stock units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 2,640,115 2,738,750
Convertibale loan notes | Private Placement Loan Notes [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 0 24,279,659
Convertibale loan notes | Novartis [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 16,308,364 15,000,137
Warrants to purchase ordinary shares    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 7,539,129 7,539,129
AstraZeneca milestones potentially payable in equity    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 1,349,692 1,349,692